Patient safety: Q&A with Masimo founder Joe Kiani

January 14, 2013 by Arezu Sarvestani

Masimo founder & CEO Joe Kiani tells MassDevice.com how closed healthcare data leads to patient injuries and deaths and the business reasons that the data has stayed closed for so long.

Masimo founder and CEO Joe Kiani

Healthcare companies are running out of reasons to keep their data behind closed doors, according to Masimo (NSDQ:MASI) founder & CEO Joe Kiani.

The technology needed to enable transparency is already here, so it comes down to a matter of leadership, he told attendees during the Patient Safety, Science & Technology Summit spearheaded by Masimo's Foundation for Ethics, Innovation & Competition in Healthcare, which took place in Laguna Beach, Calif., yesterday and today.

"I'm not any less guilty than my colleagues, who are all hoping that we'll take advantage of our own data in a way that will be very profitable," Kiani told MassDevice.com at the close of Sunday's presentations. "I think we're waking up to say, 'You know what, while we haven't thought about how to make money out of that, patients are dying.'"

Sign up to get our free newsletters delivered right to your inbox.

Kiani told us about the spirit of openness, the opportunity for healthcare to catch up with other industries in terms of information innovation, and some of the motivators behind the push for better patient safety – including the death of a 12-year-old boy.

MassDevice: Given the importance of integrated medical device data in the interest of patient safety, why has it taken so long for medtech companies to open up their data and work toward integration?

Joe Kiani: I really think people were hiding behind standards. It was a good thing to say, "We'll wait until the standards are fixed for us to begin sharing data." Just like me, I'm not any less guilty than my colleagues, who are all hoping that we'll take advantage of our own data in a way that will be very profitable. And I think we're finally waking up to say, You know what, while we haven't thought about how to make money out of that, patients are dying, people are getting harmed.

Comments

Features

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp